{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:08:54Z","timestamp":1793833734252,"version":"4.6.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T00:00:00Z","timestamp":1778371200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":75,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004398","name":"Mitsubishi Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004398","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-50505-2","type":"journal-article","created":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T14:04:41Z","timestamp":1778421881000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Sphingolipid and glycerophospholipid profiling in post-acute sequelae of SARS-CoV-2 infection"],"prefix":"10.1038","volume":"16","author":[{"given":"Shinya","family":"Yamamoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Kurano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koh","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Kubota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeya","family":"Tsutsumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junken","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoji","family":"Moriya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,10]]},"reference":[{"key":"50505_CR1","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/S0140-6736(24)01136-X","volume":"404","author":"T Greenhalgh","year":"2024","unstructured":"Greenhalgh, T., Sivan, M., Perlowski, A. & Nikolich, J. Z. Long COVID: A clinical update. Lancet 404, 707\u2013724. https:\/\/doi.org\/10.1016\/S0140-6736(24)01136-X (2024).","journal-title":"Lancet"},{"key":"50505_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lana.2024.100984","volume":"42","author":"TK Babalola","year":"2025","unstructured":"Babalola, T. K. et al. SARS-COV-2 re-infection and incidence of post-acute sequelae of COVID-19 (PASC) among essential workers in New York: A retrospective cohort study. Lancet Reg. Health Am. 42, 100984. https:\/\/doi.org\/10.1016\/j.lana.2024.100984 (2025).","journal-title":"Lancet Reg. Health Am."},{"key":"50505_CR3","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202401099R","volume":"38","author":"B Uranbileg","year":"2024","unstructured":"Uranbileg, B. et al. Comprehensive metabolic modulations of sphingolipids are promising severity indicators in COVID-19. FASEB J. 38, e23827. https:\/\/doi.org\/10.1096\/fj.202401099R (2024).","journal-title":"FASEB J."},{"key":"50505_CR4","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.jiph.2024.01.017","volume":"17","author":"PF Garrido","year":"2024","unstructured":"Garrido, P. F. et al. Lipidomics signature in post-COVID patient sera and its influence on the prolonged inflammatory response. J. Infect. Public Health 17, 588\u2013600. https:\/\/doi.org\/10.1016\/j.jiph.2024.01.017 (2024).","journal-title":"J. Infect. Public Health"},{"key":"50505_CR5","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/j.cell.2022.01.014","volume":"185","author":"Y Su","year":"2022","unstructured":"Su, Y. et al. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell 185, 881-895 e820. https:\/\/doi.org\/10.1016\/j.cell.2022.01.014 (2022).","journal-title":"Cell"},{"key":"50505_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2022.888232","volume":"16","author":"H Renz-Polster","year":"2022","unstructured":"Renz-Polster, H., Tremblay, M. E., Bienzle, D. & Fischer, J. E. The pathobiology of Myalgic Encephalomyelitis\/Chronic Fatigue Syndrome: The case for neuroglial failure. Front. Cell. Neurosci. 16, 888232. https:\/\/doi.org\/10.3389\/fncel.2022.888232 (2022).","journal-title":"Front. Cell. Neurosci."},{"key":"50505_CR7","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1002\/ana.22426","volume":"69","author":"JA Cohen","year":"2011","unstructured":"Cohen, J. A. & Chun, J. Mechanisms of fingolimod\u2019s efficacy and adverse effects in multiple sclerosis. Ann. Neurol. 69, 759\u2013777. https:\/\/doi.org\/10.1002\/ana.22426 (2011).","journal-title":"Ann. Neurol."},{"key":"50505_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2024.105942","volume":"228","author":"J Dai","year":"2024","unstructured":"Dai, J. et al. Virus infection and sphingolipid metabolism. Antivir. Res. 228, 105942. https:\/\/doi.org\/10.1016\/j.antiviral.2024.105942 (2024).","journal-title":"Antivir. Res."},{"key":"50505_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/1873-3468.70189","author":"MD Bancilhon","year":"2025","unstructured":"Bancilhon, M. D. & Mesmin, B. Reciprocal control of viral infection and phosphoinositide dynamics. FEBS Lett. https:\/\/doi.org\/10.1002\/1873-3468.70189 (2025).","journal-title":"FEBS Lett."},{"key":"50505_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1069","volume":"12","author":"M Kurano","year":"2022","unstructured":"Kurano, M. et al. Dynamic modulations of sphingolipids and glycerophospholipids in COVID-19. Clin. Transl. Med. 12, e1069. https:\/\/doi.org\/10.1002\/ctm2.1069 (2022).","journal-title":"Clin. Transl. Med."},{"key":"50505_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2023.1100486","volume":"10","author":"Y L\u00f3pez-Hern\u00e1ndez","year":"2023","unstructured":"L\u00f3pez-Hern\u00e1ndez, Y. et al. Untargeted analysis in post-COVID-19 patients reveals dysregulated lipid pathways two years after recovery. Front. Mol. Biosci. 10, 1100486. https:\/\/doi.org\/10.3389\/fmolb.2023.1100486 (2023).","journal-title":"Front. Mol. Biosci."},{"key":"50505_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-07944-4","volume":"12","author":"P Schousboe","year":"2022","unstructured":"Schousboe, P. et al. Reduced levels of pulmonary surfactant in COVID-19 ARDS. Sci. Rep. 12, 4040. https:\/\/doi.org\/10.1038\/s41598-022-07944-4 (2022).","journal-title":"Sci. Rep."},{"key":"50505_CR13","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1164\/rccm.202110-2279LE","volume":"205","author":"AD Postle","year":"2022","unstructured":"Postle, A. D. et al. Rapid phospholipid turnover after surfactant nebulization in severe COVID-19 infection: A randomized clinical trial. Am. J. Respir. Crit. Care Med. 205, 471\u2013473. https:\/\/doi.org\/10.1164\/rccm.202110-2279LE (2022).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"50505_CR14","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1152\/japplphysiol.01164.2004","volume":"98","author":"DL Poelma","year":"2005","unstructured":"Poelma, D. L., Lachmann, B., Haitsma, J. J., Zimmermann, L. J. & van Iwaarden, J. F. Influence of phosphatidylglycerol on the uptake of liposomes by alveolar cells and on lung function. J. Appl. Physiol. (1985) 98, 1784\u20131791. https:\/\/doi.org\/10.1152\/japplphysiol.01164.2004 (2005).","journal-title":"J. Appl. Physiol. (1985)"},{"key":"50505_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24010326","author":"B Tlatelpa-Romero","year":"2022","unstructured":"Tlatelpa-Romero, B., Cazares-Ordonez, V., Oyarzabal, L. F. & Vazquez-de-Lara, L. G. The role of pulmonary surfactant phospholipids in fibrotic lung diseases. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms24010326 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"50505_CR16","doi-asserted-by":"publisher","first-page":"4600","DOI":"10.1096\/fj.201701462RR","volume":"32","author":"M Martinez-Calle","year":"2018","unstructured":"Martinez-Calle, M., Olmeda, B., Dietl, P., Frick, M. & Perez-Gil, J. Pulmonary surfactant protein SP-B promotes exocytosis of lamellar bodies in alveolar type II cells. FASEB J. 32, 4600\u20134611. https:\/\/doi.org\/10.1096\/fj.201701462RR (2018).","journal-title":"FASEB J."},{"key":"50505_CR17","unstructured":"World Health Organization. Post COVID-19 condition (Long COVID), https:\/\/www.who.int\/europe\/news-room\/fact-sheets\/item\/post-covid-19-condition&gt (2022)."},{"key":"50505_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-56321-w","volume":"14","author":"B Uranbileg","year":"2024","unstructured":"Uranbileg, B. et al. Development of an advanced liquid chromatography-tandem mass spectrometry measurement system for simultaneous sphingolipid analysis. Sci. Rep. 14, 5699. https:\/\/doi.org\/10.1038\/s41598-024-56321-w (2024).","journal-title":"Sci. Rep."},{"key":"50505_CR19","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1002\/lipd.12175","volume":"54","author":"Y Morita","year":"2019","unstructured":"Morita, Y. et al. Evaluation of lysophospholipid measurement in cerebrospinal fluid samples using liquid chromatography-tandem mass spectrometry. Lipids 54, 487\u2013500. https:\/\/doi.org\/10.1002\/lipd.12175 (2019).","journal-title":"Lipids"},{"key":"50505_CR20","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1080\/10715762.2019.1641603","volume":"53","author":"M Kurano","year":"2019","unstructured":"Kurano, M., Yasukawa, K., Ikeda, H., Aoki, J. & Yatomi, Y. Redox state of albumin affects its lipid mediator binding characteristics. Free Radic. Res. 53, 892\u2013900. https:\/\/doi.org\/10.1080\/10715762.2019.1641603 (2019).","journal-title":"Free Radic. Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-50505-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-50505-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-50505-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T23:03:09Z","timestamp":1784847789000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-50505-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,10]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["50505"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-50505-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,10]]},"assertion":[{"value":"26 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Masayuki Kubota is an employee of Nipon Waters Co.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study design received approval from the University of Tokyo Medical Research Center Ethics Committee (2020206NI).","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During preparation of this work the author used ChatGPT, (OpenAI, San Francisco, California, USA; GPT-5 model) in order to English proofreading to improve the clarity and fluency of the manuscript written by the author. After using this tool, the author reviewed and edited the content as needed and take full responsibility for the content of the publication.","order":3,"name":"Ethics","label":"AI declaration","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"23133"}}